At Acadia, we are dedicated to bringing innovative medicines to patients with central nervous system (CNS) disorders. We are committed to partnerships and collaborations to expand access to our future products and to complement our portfolio of product candidates.
As part of our strategy, we selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In areas where our products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we plan to commercialize our product candidates in the United States. In therapeutic areas that require large specialty or primary care sales forces, we may choose to conduct commercialization through, or in collaboration with, partners. We plan to commercialize our products in markets outside of the United States on our own or by establishing strategic alliances.
We welcome the opportunity to learn more about how we can work together. To further explore partnering opportunities with Acadia, please contact us.
Acadia and Neuren Pharmaceuticals Limited have an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Rett syndrome is a debilitating neurological disorder that occurs primarily in females following apparently normal development for the first six months of life.
Acadia and Vanderbilt University have an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of CNS disorders. The collaboration is focused on positive allosteric modulators (PAMs) of the M1 receptor. Highly selective PAMs of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders.